Genmab — April 2018
-
God morgen.
-
God morgen.
Jeg har ikke fået salgstal. -
God morgen
-
https://twitter.com/DrKantor/status/989020060579704832 - Poster : Ofatumumab (subcutaneous anti-CD20) effects on white blood cells in mice vs. IV version
-
-
Effect of Subcutaneous vs Intravenous Chronic Treatment with an Anti-CD20 Antibody on B-, T- and Myeloid Lymphocyte Subsets in Blood, Lymph Nodes and Spleen of C57BL/6 Mice (P2.410)
Anna Schubart, Gaelle Elain, Cindy Schmid, Julien Perdoux, Catherine Huck, David Leppert, Anis Mir, Gisbert Weckbecker
Neurology Apr 2018, 90 (15 Supplement) P2.410 -
Chronic s.c. administration of an anti-CD20 antibody in mice induced a potent and long-lasting depletion of B cells. The quicker B-cell recovery in spleen with s.c. versus i.v. treatment may be linked to more favorable immunosurveillance and thereby may provide a potential benefit for patients requiring treatment cessation
-
yes, also in that article from gentogen, here the link http://n.neurology.org/content/90/15_Supplement/P2.410
I can't wait to see the Ofa results in MS
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind